Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 6/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7277359 | 0.76 | KCNJ1 (0.38) | KCNJ1ALDH1A1MEN1KMT2A | |
| SCHEMBL5278040 | 0.74 | KCNJ1 (0.36) | KCNJ1ALDH1A1MEN1KMT2A | |
| SCHEMBL8401872 | 0.73 | KCNJ1 (0.41) | KCNJ1ALDH1A1MEN1KMT2A | |
| SCHEMBL4502875 | 0.72 | — | — | |
| SCHEMBL707611 | 0.70 | — | — | |
| SCHEMBL2337290 | 0.70 | KCNJ1 (0.39) | KCNJ1ALDH1A1MEN1KMT2A | |
| SCHEMBL4971138 | 0.70 | P2RX4 (0.35) | P2RX4 | |
| SCHEMBL2183929 | 0.67 | BCHE (0.39) | ALDH1A1P2RX4KMT2A | |
| SCHEMBL13102423 | 0.67 | KCNJ1 (0.41) | KCNJ1ALDH1A1MEN1KMT2A | |
| SCHEMBL8399476 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283977-A1 | USE OF PREPARATION FOR INHIBITING OR BLOCKING INTERACTION BETWEEN FAAH AND NLRP3 | 华南理工大学 | 2023-01-19 | — | — | WO | disclosed |
| US-20160139162-A1 | Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors | NORTHEASTERN UNIVERSITY | 2016-05-19 | — | — | US | disclosed |
| US-20160139162-A1 | Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors | NORTHEASTERN UNIVERSITY | 2016-05-19 | — | — | US | disclosed |
| US-9271962-B2 | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors | NORTHEASTERN UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271962-B2 | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors | NORTHEASTERN UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-07-07 | — | — | US | disclosed |
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-07-07 | — | — | US | disclosed |
| WO-2009117444-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE AND MONOACYLGLYCEROL LIPASE FOR MODULATION OF CANNABINOID RECEPTORS | NORTHEASTERN UNIVERSITY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | FAAH, FAAH2, MGLL | KCNJ1 4141/4885DAGLA 10/4885ALDH1A1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.